LONDON, Dec. 13, 2018 /PRNewswire/ -- PEGylated Protein Therapeutics Market by Product Type (Colony Stimulating Factor, Interferon, Erythropoietin (EPO), Recombinant Factor VIII, Monoclonal Antibody, Enzyme, and Others) By Application (Cancer, Autoimmune Disease, Hepatitis, Multiple Sclerosis, Hemophilia, Gastrointestinal Disorder, and Others) By Sales Channel (Hospital Pharmacy, Online Provider, and Retail Pharmacy) - Global Opportunity Analysis and Industry Forecast, 2018-2025Download the full report: https://www.reportbuyer.com/product/5563992
PEGylation refers to the process of amalgamation or attachment of polyethylene glycol (PEG) polymer chains with macromolecules, such as drug molecule, therapeutic protein, or vesicles by covalent bonding. PEGylation offers several advantages, such as improved drug solubility, reduced dosage frequency, and increased drug stability, which boost its demand in the market.The global PEGylated protein therapeutics market was valued at $10,388 million in 2017, and is estimated to reach at $17,813 million by 2025, registering a CAGR of 6.9% from 2018 to 2025. The factors that propel the PEGylated protein therapeutics market growth include high prevalence of chronic diseases, such as cancer, kidney diseases, and rheumatoid arthritis. In addition, growth in the biologics sector with an increase in R&D expenditure of pharmaceutical and biopharmaceutical companies boosts the market. Furthermore, increase in government funding and grants for research activities enhance opportunities for the growth of the market. However, high price, and expected launch of generic drugs can hinder the growth.The global PEGylated protein therapeutics market is segmented based on product type, application, sales channel, and region. According to the product type, the market is classified into colony stimulating factor, interferon, erythropoietin, recombinant factor VIII, monoclonal antibody, enzyme, and others. Based on application, the market is categorized into cancer, autoimmune disease, hepatitis, multiple sclerosis, hemophilia, gastrointestinal disorder, and others. According to the sales channel, it is segmented into hospital pharmacy, online provider, and retail pharmacy. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).Key players profiled in the report include Amgen Inc., AstraZeneca PLC, Biogen, Inc., F. Hoffmann-La Roche Ltd. (Genentech, Inc.,), Horizon Pharma plc., Leadiant Biosciences S.p.A., Merck & Co., Inc. (Schering-Plough Corporation), Pfizer Inc., Shire plc (Baxalta), and UCB S.A.KEY BENEFITS FOR STAKEHOLDERSThe study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.KEY MARKET SEGMENTSBy Product TypeColony Stimulating FactorInterferonErythropoietin (EPO)Recombinant Factor VIIIMonoclonal AntibodyEnzymeOthersBy Application TypeCancerAutoimmune DiseaseHepatitisMultiple SclerosisHemophiliaGastrointestinal DisorderOthersBy Sales ChannelHospital PharmacyOnline ProviderRetail PharmacyBy RegionNorth AmericaU.S.CanadaMexicoEuropeGermanyFranceUKItalySpainRest of EuropeAsia-PacificJapanChinaAustraliaIndiaSouth KoreaRest of Asia-PacificLAMEABrazilSaudi ArabiaSouth AfricaRest of LAMEALIST OF KEY PLAYERS PROFILED IN THE REPORTAmgen Inc.AstraZeneca PLCBiogen, Inc.F. Hoffmann-La Roche Ltd. (Genentech, Inc.,),Horizon Pharma plc.Leadiant Biosciences S.p.A.Merck & Co., Inc. (Schering-Plough Corporation)Pfizer Inc.Shire plc (Baxalta)UCB S.A.Download the full report: https://www.reportbuyer.com/product/5563992
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith
Research Advisor at Reportbuyer.com Email: [email protected]
Tel: +1 (718) 213 4904 Website: www.reportbuyer.com
Advertisement
View original content:http://www.prnewswire.com/news-releases/the-global-pegylated-protein-therapeutics-market-was-valued-at-10-388-million-in-2017--and-is-estimated-to-reach-at-17-813-million-by-2025--registering-a-cagr-of-6-9-from-2018-to-2025--300765163.html
SOURCE ReportBuyer
